Experts discuss the recently FDA-approved nirsevimab for the prevention of Respiratory Syncytial Virus (RSV) for late-preterm and term infants, highlighting a recent study on the safety and efficacy of nirsevimab.
EP. 2: Prevalence and Clinical Gaps of RSV
September 18th 2023Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, discuss the prevalence of Respiratory Syncytial Virus (RSV) and prior preventative gaps. They also discuss the recent FDA-approval of nirsevimab for late-preterm and term infants.
EP. 6: Time-To-Event Analysis and Discussion on the Efficacy Nirsevimab for RSV
September 18th 2023Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, continue their discussion on the results of nirsevimab for Respiratory Syncytial Virus (RSV) and offer insights on how this may change therapeutic approaches in the future.
EP. 8: Infant Weight and Efficacy Outcomes of Nirsevimab for RSV
September 18th 2023Experts discuss how infant weight related to efficacy outcomes of nirsevimab for Respiratory Syncytial Virus (RSV), providing their clinical expertise on why this may have occurred and what improvements can be made to mitigate these differences.